Creo Medical Group plc (AIM: CREO), the medical device company focused on minimally invasive electrosurgical technologies, announces positive clinical feedback following the use of SpydrBlade™ in Bariatric Endoscopic Antral Myotomy (“BEAM”) procedures.

Professor Chris Thompson, a globally recognised leader in gastrointestinal and bariatric endoscopy and widely regarded as the inventor of the BEAM technique, has successfully performed two BEAM procedures using SpydrBlade™.

Professor Thompson recently presented these cases at the Foundation of Endoscopic Surgery (FES) educational course, supporting awareness of both the BEAM procedure and the role of SpydrBlade™ within the advanced endoscopy community.

BEAM is an incision‑less endoscopic bariatric procedure intended to slow gastric emptying through targeted antral myotomy, offering patients a less invasive alternative to surgical bariatric interventions. Early‑stage studies reported in the peer‑reviewed literature indicate meaningful weight loss outcomes and delayed gastric emptying, although larger‑scale data remain ongoing.

The global obesity epidemic represents a substantial and growing healthcare challenge, and Endoscopic Bariatric and Metabolic Therapies (“EBMT”) are estimated to represent a multi‑billion‑dollar global market, driven by increasing demand for minimally invasive options that bridge the gap between pharmacological therapy and surgery.

The Company believes that BEAM represents an emerging application within advanced therapeutic endoscopy that aligns closely with Creo’s strategic focus on complex gastrointestinal procedures. SpydrBlade™ is a core component of Creo’s GI portfolio and is designed to support precise tissue dissection and controlled haemostasis across a range of advanced endoscopic interventions. Successful use of SpydrBlade™ in procedures such as BEAM reinforces its potential to drive broader adoption across existing and future GI indications.